Good morning, and thank you for joining the first quarter 2021 ReShape Life Sciences Earnings Webinar. I'm pleased to be joined by Bart Bandy, Chief Executive Officer of ReShape Lifesciences Inc., who will provide an overview of the company's recent activities and business highlights for the first quarter of 2021. Tom Stankovich, Chief Financial Officer of ReShape, will then review the financial results for the first quarter and then turn the call back over to Bart to finish. As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website at www.reshapelifesciences.com, including the Investor Information section of the website, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as risk factors in our annual report on Form 10-K and in our quarterly report on Form 10-Q that was filed yesterday. As an additional reminder, our stock is listed OTC, trading under the ticker RSLS. I will now turn the call over to the CEO, Bart Bandy. Bart?

Thanks, James. Good morning, everyone, and thank you for joining us today. The first quarter of 2021 was very productive for ReShape, as we were able to expand the ReShape product portfolio and saw LAP-BAND purchases continue to build from the pandemic with both existing and recommenced accounts. Additionally, one of our highest priorities in the first half of this year has been completing our merger with Obalon and the associated uplisting to NASDAQ. I am pleased to announce that this process continues to progress, including the recent approval of the merger by shareholders holding approximately 95% of our common stock during our shareholder meeting on May 13, 2021. The completion of this merger will create numerous opportunities for our company as the combined company would also begin trading on NASDAQ following the completion of this transaction. Obalon's technology is the first and only swallowable gas-filled balloon system for weight loss and has continued to demonstrate strong efficacy and a best-in-class safety profile for weight loss with lasting results and minimal side effects. In addition to weight loss, patients showed improvement in cardiometabolic risk factors, including fasting glucose, systolic blood pressure, cholesterol and triglycerides. The potential addition of this technology illustrates our mission to build a portfolio of regulatory approved solutions for desired outcomes achieved in conjunction with patient-centric care and data-based best-in-class safety profiles. We are also pleased with the efforts we made during the first quarter in driving the sustainability of our blended products and service portfolio in line with current market trends. In 2020, the World Health Organization encouraged the use of telehealth instead of physical hospital visits to minimize the risk of individuals contracting COVID-19. We have capitalized on this major multimillion-dollar market opportunity with the launch of our ReShapeCare service. ReShapeCare is a reimbursed telehealth-enabled…

Thanks, Bart, and good morning to everyone. First quarter of 2021 proved to be encouraging as compared to the same time last year. For the 3 months ended March 31, 2021, we reported revenues of $3.2 million as compared to revenues of $2.8 million in the 3 months ended March 31, 2020, representing a 15.5% increase. The $400,000 increase was primarily due to greater U.S. sales and was partially offset by a decrease of international sales resulting from several regions heavily affected by the COVID-19 pandemic. We reported gross profit of $2.3 million in the first quarter of 2021, representing a gross margin of 71% compared to $1.5 million in the 3 months ended March 31, 2020, at a gross margin of 54%. The higher gross margin is attributed to increased volume, lower overhead expenses and improved product mix with higher domestic sales, which historically have a greater gross profit margin than international sales. Total operating expenses for the 3 months ended March 31, 2021, decreased by $1.1 million to $4.5 million as compared to $5.6 million for the 3 months ended March 31, 2020. Sales and marketing expenses for the first quarter of 2021 were $1.3 million as compared to $1.5 million for the first quarter of 2020. This decrease stems from lower payroll-related expenses and a reduction in consulting fees. As we center our focus on further tapping into the strong potential and positive return of the weight loss market, we expect to increase our advertising and marketing expenditure for the remainder of 2021. General and administrative expenses were $2.7 million for the 3 months ended March 31, 2021 compared with $2.8 million for the 3 months ended March 31, 2020. The $100,000 decrease was primarily related to the absence of stock option grants, reduced bad debt expense…

Thanks, Tom. We believe we are well positioned to continue to penetrate the physician-led weight loss market with our safe and effective weight loss solutions. Additionally, we are confident that directly reaching more of our customer base will improve shareholder value. Our potential uplisting to NASDAQ will provide greater interest within the investment community and offer our shareholders an opportunity for increased value and liquidity. Despite the constraints of the pandemic, I am very pleased with the forward progress, sustainable business model and robust platform we have continued to develop at ReShape. Thank you to our investors, employees, Board and customers for your continued support of the vision and mission of ReShape.